IGOS
A world widestudy on biomarkers and outcomes in GBS
GBS
Guillain-Barré syndrome (GBS) has a profound impact on patients and their families. Researchers have made considerable progress in understanding the disease mechanisms. Unfortunately, these achievements have not resulted in finding better treatments for GBS so far.
The current standard treatment of GBS with either intravenous immunoglobulins (IVIg) or plasma exchange (PE) has not changed much in the last 30 years; more effective treatments are still needed.
2012
In 2012 an international team of expert neurologists and scientists decided to join forces and start the International GBS Outcome Study (IGOS), aiming to collect the world’s largest high-quality data/biobank for further research.
2016
By 2016 – 100 years since the description of Guillain Barré Syndrome – the international team had expanded considerably. Nowadays the IGOS Consortium consists of researchers and clinicians from 143 centres in 21 countries across 5 continents.
2024
Together we included 2000 patients with the Guillain-Barré Syndrome (GBS) from 21 countries across 5 continents. All patients diagnosed with GBS are included, independent of age, severity, variant, treatment, and disease course.
IGOS is the largest real-world database on GBS worldwide containing clinical data, biomaterial, electrophysiology and questionnaires on patient-reported outcome measures. Data are collected at standardized timepoints for up to three years after hospital admission. Follow-up was finalized in May 2024.
